Hotchkiss, K. M., Norberg, P., Buckley, E., Ayasoufi, K., Threatt, S., Low, J. T., … Khasraw, M. (2025). OS04.3.A P30-EPS PEPTIDE VACCINE IS SAFE AND IMMUNOGENIC IN NEWLY DIAGNOSED GLIOBLASTOMA: A PHASE 1B TRIAL. In Neuro-Oncology (Vol. 27, pp. iii14–iii14). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noaf193.042

Hotchkiss, K. M., P. Norberg, E. Buckley, K. Ayasoufi, S. Threatt, J. T. Low, M. L. Shoaf, et al. “OS04.3.A P30-EPS PEPTIDE VACCINE IS SAFE AND IMMUNOGENIC IN NEWLY DIAGNOSED GLIOBLASTOMA: A PHASE 1B TRIAL.” In Neuro-Oncology, 27:iii14–iii14. Oxford University Press (OUP), 2025. https://doi.org/10.1093/neuonc/noaf193.042.

Hotchkiss KM, Norberg P, Buckley E, Ayasoufi K, Threatt S, Low JT, et al. OS04.3.A P30-EPS PEPTIDE VACCINE IS SAFE AND IMMUNOGENIC IN NEWLY DIAGNOSED GLIOBLASTOMA: A PHASE 1B TRIAL. In: Neuro-Oncology. Oxford University Press (OUP); 2025. p. iii14–iii14.

Hotchkiss, K. M., et al. “OS04.3.A P30-EPS PEPTIDE VACCINE IS SAFE AND IMMUNOGENIC IN NEWLY DIAGNOSED GLIOBLASTOMA: A PHASE 1B TRIAL.” Neuro-Oncology, vol. 27, no. Supplement_3, Oxford University Press (OUP), 2025, pp. iii14–iii14. Crossref, doi:10.1093/neuonc/noaf193.042.

Hotchkiss KM, Norberg P, Buckley E, Ayasoufi K, Threatt S, Low JT, Shoaf ML, Goldston M, Batich K, Johnson MO, Nair S, Weinhold K, Friedman HS, Ashley DM, Desjardins A, Sampson JH, Khasraw M. OS04.3.A P30-EPS PEPTIDE VACCINE IS SAFE AND IMMUNOGENIC IN NEWLY DIAGNOSED GLIOBLASTOMA: A PHASE 1B TRIAL. Neuro-Oncology. Oxford University Press (OUP); 2025. p. iii14–iii14.